Table 1. Patients’ demographic, clinical and laboratory parameters at baseline and whole study period of 2 years.
| Variable | Parameter | |
| Baseline | Total number of patients, N (%) | 323 (100%) |
| Gender, N (%) | ||
| Male | 235 (72.8%) | |
| Female | 87 (26.9%) | |
| Transgender | 1 (0.3%) | |
| Age, Mean (SD), years | 38 (8.5) | |
| Duration of treatment, Mean (SD), months | 23 (11) | |
| CD4 cell count, Median (IQR), cells/mm3 | 370 (243–525) | |
| Drug regimen at baseline, N (%) | ||
| d4T+3TC+NVP | 123 (38.1%) | |
| AZT+3TC+NVP | 160 (49.5%) | |
| d4T+3TC+EFV | 21 (6.5%) | |
| AZT+3TC+EFV | 17 (5.3%) | |
| FTC+TDF+EFV | 1 (0.3%) | |
| DDI+3TC+NVP | 1 (0.3%) | |
| Follow-up* | Intermittent viral rebound, N (%) | 51 (15.8%) |
| Virological failure, N (%) | 9 (2.8%) | |
| Treatment Interruptions, N (%) | 29 (9.0%) | |
| ≥ 95% Adherence, N (%) | 243 (75.2%) | |
| Perfect Adherence, N (%) | 153 (47.4%) | |
| Duration of viral suppression Median (IQR), years | 44 (36–54) |
Abbreviations: d4T, Stavudine; 3TC, lamivudine; AZT, zidovudine; FTC, emtricitabine; TDF, tenofovir; NVP, Nevirapine; EFV, Efavirenz; SD, Standard deviation; IQR, interquartile range; N, Number; PVL, plasma viral load; VAS, Visual analogue scale.
*
Over the study period of 2 years,